TORONTO, May 12, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) is pleased to welcome Dr. Claudia Jiménez (Ph.D.) to its board of directors. As a board member, Dr. Jiménez will also serve on the Company's Audit, Nominating and Corporate Governance committees. Dr. Jiménez's appointment is effective June 1, 2020.
Dr. Jiménez's career and experience span across government, academia and private sectors where she held various senior leadership and advisory roles. In this capacity, she has served as Minister-Counselor for the President of Colombia, Ambassador in Switzerland and Liechtenstein, Executive Director of the Mining Colombian Association (SMGE) and as a professor at the University Externado de Colombia where she taught economic law.
"We are pleased to have Dr. Jiménez joining the board of PharmaCielo where she will bring her extensive multidisciplinary and external Canadian board experience to bolster the Company's capabilities and support our business growth both in Colombia and into international markets," says Simon Langelier, Chairman of the Board. "Over the past couple of years Dr. Jiménez has proven herself an astute advisor serving on the PharmaCielo Colombia SAS board of directors, and she will be a tremendous asset serving on the global board."
Dr. Jiménez is a Colombia-based lawyer and General Manager of Jiménez & Asociados S.A.S., a private consultancy firm that provides fiscal, financial and economic advisory services. Dr. Jiménez graduated with a degree in Law and Political Science from the Universidad Pontificia Bolivariana in Medellín, Colombia, and later completed a Doctorate of Law at the Université of Paris II (Panthéon-Assas), France. Dr. Jiménez is a member of the board of directors of ISA InterColombia, is Executive Director of the Dialogue Group of Mining in Colombia (GDIAM) and a former board member of Empresas Públicas de Medellín (EPM) and TSX-listed Continental Gold.
PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Toronto, Canada, focused on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to global markets through large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in the leading agricultural region of Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.
Forward Looking Statements:
Certain statements contained in this news release, such as those relating the appointment date of Dr. Jiménez as a director of the Company, the business growth of the Company in Colombia and international markets contain "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including the Company's ability to execute its business plan and obtain necessary government and TSXV approvals related to conducting its business. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the Company's failure to obtain necessary TSXV or applicable government regulatory approvals in relation to its business, the Company being unable to export or distribute commercial product to its sale channels due to economic or operational circumstances, risks associated with operating in Colombia, risks associated with global economic instability relating to COVID-19 and currency exchange risk, as well as the other risks and uncertainties applicable to cannabis producing companies and to the Company. The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE PharmaCielo Ltd.
For further information: David Gordon, Chief Corporate Officer, +1 416-864-6116, www.PharmaCielo.com; Media Relations: International: Gal Wilder, Cohn & Wolfe, +1 647-259-3261, [email protected]; Colombia: María Paula Peña Fdz., SPR GROUP S.A., PBX: 57-1 2877234, [email protected]; Investor Inquiries: [email protected]